Pfizer's Execution Finesse: Beating Estimates, Betting on Obesity and Oncology

Q2 2026: revenue guidance raised, EPS maintained, while COVID slides and pipeline readouts loom.

PFE · Earnings Call · 2026-08-04

A Quarter of Discipline

Pfizer's Q2 2026 was another demonstration of executional precision. Revenue of $14.5B beat expectations, and the company raised its full-year revenue guidance by $500M, while reaffirming EPS guidance. CEO Albert Bourla noted, “We had another strong quarter of execution, driving continued strategic progress.” — Albert Bourla, Chairman and Chief Executive Officer · 2026-08-04 The underlying business expanded 5% operationally ex-COVID, with launched and acquired products growing 18% operationally. Total Revenue performance was supported by Eliquis, Padcev, the Vyndaqel family, and Lorbrena.

Cost Savings and Financial Discipline

The company expanded its cost realignment program, now expecting $9.7B in total net savings through 2029. CFO Cecile Guegan said, “Our business is performing well. Commercial execution is driving strong results, including 18% operational revenue growth in our launched and acquired products this quarter.” — Cecile Guegan, Incoming Chief Financial Officer · 2026-08-04 This discipline is central to Net cost savings and preserving margins.

Oncology and Obesity: The Growth Engines

Oncology remains a clear strength. Padcev's label expansion to muscle-invasive bladder cancer, and the upcoming MEVPRO-1 readout for mevrometostat in Q4 are key catalysts. Chris Boshoff highlighted, “MEVPRO-1 is event-driven ... we expect the first readout for MEVPRO-1 in the fourth quarter based on the current event rate.” — Chris Boshoff, Chief Oncology Research and Development Officer · 2026-08-04 Mevrometostat could extend the prostate franchise. In obesity, the company is advancing berobenatide, a potential first monthly GLP-1. berobenatide data showed competitive efficacy, and the company plans 10 Phase III studies in 2026.

Dividend and Capital Allocation

Albert Bourla was unequivocal about the dividend:

We feel extremely confident that we will -- even the most stretched scenarios that we are running, we will be able to maintain our dividend.
Albert Bourla, Chairman and Chief Executive Officer · 2026-08-04

This commitment is supported by strong cash flow and disciplined capital allocation, with BD capacity around $6B after the Innovent deal.

COVID: The Declining Offset

COVID revenue is now expected at $4B, down from $5B, but the company's non-COVID strength more than offsets. "Our commercial performance has also helped mitigate the impact of currently low COVID infection levels," noted Guegan. Prior quarters show similar focus on execution and cost discipline. In May, Bourla said, “Our strong performance in the quarter reflects the impact of our continued focus and disciplined execution.” — Albert Bourla, Chairman and Chief Executive Officer · 2026-05-05 In February, Denton mentioned “we do have $7 billion in BD capacity.” — David Denton, Chief Financial Officer · 2026-05-05